Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
70 | Publisher: RNCOS
Industry: Healthcare | Report Format: Electronic (PDF)
Psoriasis is a chronic, non-communicable, painful, disfiguring and disabling disease. This disease causes rapid build-up of skin cells. This disease can occur at any age, and is most common in the age group of 50-69 years. According to World Health Organization, the prevalence of psoriasis in different countries ranges between 0.09% and 11.4%. Treatment of this disease is based on controlling of its symptoms. Topical and systemic therapy drugs are used in combination, in order to combat this disease. As per RNCOS report "Global Psoriasis Drugs Market by Drug Molecule (Biologic, Small Molecule Drugs), By Route of Administration (Systemic, Topical), By Mechanism of Action (TNF Inhibitors, Interleukin Blockers) Outlook 2022", the global psoriasis drugs market is anticipated to witness a high growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market. The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe. Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs. Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global psoriasis drugs market. Moreover, the report also highlights various mergers and acquisitions taking place in the global psoriasis drugs industry. The pipeline of psoriasis drugs have also been mentioned in the report. The last section of the report discusses about the prominent players in global psoriasis drugs market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global psoriasis drugs market.
Table of Contents
1. Analyst View 2. Research Methodology 3. Psoriasis: An Overview 4. Market Dynamics 4.1 Drivers 4.1.1 Rising Prevalence of Psoriasis 4.1.2 Increasing Awareness 4.1.3 Growing Geriatric Population 4.1.4 Rising Healthcare Expenditure 4.2 Challenges 4.2.1 Patent Cliff of Blockbuster Drugs 4.2.2 High Cost 4.3 Opportunities 4.3.1 Biologic Drugs Flaring Up Psoriasis Drugs Market 4.3.2 Incessant Launch of Novel Products 5. Global Psoriasis Drugs Market Outlook 2022 6. Market Segmentation by Type of Drug Molecule 6.1 Biologic Drugs 6.2 Small Molecule/Chemical Drugs 7. Market Segmentation by Route of Administration 7.1 Systemic 7.2 Topical 8. Market Segmentation by Mechanism of Action 8.1 TNF Inhibitors 8.2 Interleukin Blockers 8.3 Others 9. Market Segmentation by Geography 9.1 North America 9.2 Europe 9.3 Asia-Pacific 10. Trends & Developments 10.1 Interleukin Inhibitors Driving Psoriasis Drugs Market 10.2 TNF-alpha Blockers for the Treatment of Psoriasis 11. Mergers, Acquisitions & Collaborations 12. Pipeline Analysis 13. Porter's Five Forces Analysis 14. Key Players 14.1 AbbVie Inc. 14.2 Biocon 14.3 Pfizer Inc. 14.4 Novartis 14.5 Eli Lilly and Company. 14.6 Celltrion Inc. 14.7 Celgene Corporation 14.8 Johnson & Johnson 14.9 Dr.Reddy's Laboratories 14.10 Amgen Inc.
List of Tables: Table 11-1: Mergers, Acquisitions & Collaborations in Psoriasis Drugs Market (2014-2016) Table 12-1: Global - Psoriasis Drugs Pipeline Analysis Table 14-1: AbbVie Inc. - Financials (Million US$), 2013, 2014 & 2015 Table 14-2: Biocon - Financials (Million US$), FY 2014, FY 2015 & FY 2016 Table 14-3: Pfizer Inc. - Financials (Million US$), 2013, 2014 & 2015 Table 14-4: Novartis - Financials (Billion US$), 2014, 2015 & 2016 Table 14-5: Eli Lilly and Company - Financials (Billion US$), 2013, 2014 & 2015 Table 14-6: Celltrion Inc. - Revenue (Billion US$), 2013, 2014 & 2015 Table 14-7: Celgene Corporation - Revenue (Billion US$), 2013, 2014 & 2015 Table 14-8: Johnson & Johnson - Total Sales (Billion US$), 2013, 2014 & 2015 Table 14-9: Dr. Reddy's - Total Sales (Billion US$), 2014, 2015 & 2016 Table 14-10: Amgen Inc. - Revenue, (Billion US$), 2013, 2014 & 2015
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.